IndieBio

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

FREZENT is a biotechnology company that develops novel therapeutics for advanced-stage cancer patients.

Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

Dandelion is a therapeutic company that focuses on training AI models that can design organ and cell-type-specific drug delivery vehicles. Dandelion was founded in 2022.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Proteinea is a biotechnology company that specializes in developing biotherapeutics by utilizing advanced protein engineering techniques. The company has created a platform that employs proprietary artificial intelligence models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. By integrating novel deep-learning models with smart experimental throughput, Proteinea aims to streamline the process of biologics design for antibody medicines. This innovative approach allows clients to evaluate the efficacy, yield, safety, and pharmacological properties of their products more effectively, ultimately leading to smarter and faster development of therapeutic solutions.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Proteinea is a biotechnology company that specializes in developing biotherapeutics by utilizing advanced protein engineering techniques. The company has created a platform that employs proprietary artificial intelligence models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. By integrating novel deep-learning models with smart experimental throughput, Proteinea aims to streamline the process of biologics design for antibody medicines. This innovative approach allows clients to evaluate the efficacy, yield, safety, and pharmacological properties of their products more effectively, ultimately leading to smarter and faster development of therapeutic solutions.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Synthetix is a decentralized protocol based on the Ethereum blockchain that facilitates the issuance of synthetic assets for derivatives trading in decentralized finance (DeFi). Founded in 2017 by Kain Warwick in Sydney, Australia, Synthetix enables users to create and trade synthetic assets that provide exposure to various real-world assets, including currencies, commodities, stocks, and indices. The platform supports a range of financial products such as perpetual futures and options markets, allowing for peer-to-contract trading with infinite liquidity. Synthetix operates through a distributed collateral pool, ensuring users can access synthetic versions of both fiat and cryptocurrencies while maintaining an overview of the entire network.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Advanced Microbubbles Inc specializes in developing microbubbles as ultrasound contrast agents for targeted drug delivery, particularly in overcoming significant biological barriers like the blood-brain barrier and tumor endothelium. Founded in 2020 and based in Newark, California, the company offers a range of products including size-isolated microbubbles, polydisperse microbubbles, and biotin- or streptavidin-tagged variants. These microbubbles are agitated with ultrasound at the tumor site, facilitating the local delivery of drugs by temporarily opening barriers that typically hinder treatment. By enabling more effective drug delivery, Advanced Microbubbles aims to reduce side effects and improve survival outcomes for patients with various neurological conditions and cancer.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

11 Biomics LLC is a biotechnology company based in Albuquerque, New Mexico, specializing in the development of biological therapeutics for the cannabis industry. The company focuses on providing innovative solutions for the treatment and protection of cannabis and hemp against fungal and bacterial diseases. As an early-stage enterprise, 11 Biomics emphasizes community involvement in its operations and aims to contribute to the growth and sustainability of the cannabis sector through its scientific advancements.

Convalesce Inc. is a therapeutic company based in San Francisco, California, focused on developing stem cell-based therapies for neurodegenerative conditions, particularly Parkinson's disease. Founded in 2018, Convalesce utilizes advanced biomaterials to enhance the efficacy of stem cell treatments. Their innovative implantable biomaterials aim to improve stem cell survival and facilitate the differentiation of these cells into neurons after implantation. By addressing critical challenges in stem cell therapy, Convalesce seeks to enable healthcare professionals to regenerate neuronal networks lost due to degeneration, ultimately offering new hope for patients suffering from debilitating neurological disorders.

Osiris Bio

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Nivien Therapeutics developed the first small molecule inhibitors of the Hippo signaling pathway. Read the Nivien story in The Washington Post: https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/

Neurocarrus Inc. is a biotechnology company based in Lincoln, Nebraska, focused on developing innovative drug delivery technologies to address pain management. Established in 2017, the company has created a non-opioid therapeutic, N-001, which utilizes protein engineering to target sensory neurons and effectively "freeze" pain signals before they reach the brain. Laboratory and animal studies suggest that N-001 offers comparable pain relief to opioids while lasting longer, positioning it as a vital alternative amid the ongoing opioid crisis. This novel approach aims to enhance the quality of life for individuals suffering from chronic pain, particularly those with tissue injuries, inflammation, or acute nerve damage. Furthermore, Neurocarrus holds exclusive rights to its drug and delivery system, which may also serve as a platform for future partnerships and therapeutic developments related to sensory neuron needs.

Onconetics Pharmaceuticals, Inc. is a biotechnology company based in Mill Valley, California, focused on developing personalized gene therapies for cancer and other genetic disorders. Established in 2016, the company employs a unique therapeutic platform that utilizes a genetic switch to activate an apoptotic inducer, selectively targeting and eliminating tumor cells while preserving healthy tissue. This innovative approach combines established gene therapy techniques with advanced research to create treatments that aim to improve patient outcomes by reducing the invasiveness and side effects associated with traditional therapies. Onconetics seeks to advance the field of personalized medicine by offering simpler, versatile therapies that prioritize patient safety and quality of life.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for diseases with significant unmet medical needs. Founded in 2014 and headquartered in Toronto, Canada, the company specializes in the creation of small molecule drugs targeting challenging and previously undruggable biological pathways. Utilizing a proprietary platform that integrates innovative synthesis design, computational modeling, and patient-derived cell-based screening, Proteorex aims to expedite the drug discovery process while reducing costs. The company's research primarily emphasizes oncology, leveraging protein-protein interactions to identify and develop new therapeutic candidates. Additionally, Proteorex operates an office in San Francisco, enhancing its reach and collaboration potential within the biotechnology landscape.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative treatments for incurable cancers and neurodegenerative diseases. Founded in 2017 and based in San Diego, California, the company utilizes a machine vision and learning platform to drive diseased stem cells toward non-diseased states. Its proprietary technology, known as microscopic imaging of epigenetic landscapes (MIEL), facilitates the discovery of small molecules that can induce epigenetic changes, allowing for the differentiation or reversal of cancerous cells into benign types, which holds potential for curative outcomes. Additionally, Stelvio is pursuing a personalized approach to glioblastoma treatment, leveraging its team's expertise in scientific innovation and clinical management to advance novel drug therapies and precision medicine diagnostics.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, focused on developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. Established in 2016, the company utilizes a unique computational design platform called SCULPT™, which integrates experimentally determined target characteristics to systematically create therapeutic candidates. A2A Pharmaceuticals employs advanced therapeutic design methodologies to inhibit protein-protein interactions and applies bioinformatics tools specifically for gram-negative bacterial species. In addition to drug development, the company also provides consulting services aimed at enhancing healthcare professionals' abilities to treat complex diseases.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, focused on developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. Established in 2016, the company utilizes a unique computational design platform called SCULPT™, which integrates experimentally determined target characteristics to systematically create therapeutic candidates. A2A Pharmaceuticals employs advanced therapeutic design methodologies to inhibit protein-protein interactions and applies bioinformatics tools specifically for gram-negative bacterial species. In addition to drug development, the company also provides consulting services aimed at enhancing healthcare professionals' abilities to treat complex diseases.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. The company specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. Girihlet has developed patented technologies for profiling T cell receptors and sequencing mitochondrial DNA, utilizing novel, bias-free methods to analyze these genetic components. This approach aims to harness the potential of T cell receptors and mtDNA as biomarkers for diagnostics across various disorders, particularly those driven by T-cell-related autoimmune conditions. By employing deep sequencing and machine learning, Girihlet seeks to decode individual immune responses and guide effective therapeutic strategies, thereby contributing significantly to both clinical applications and advanced research in immunology.

BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.

LizarBio Therapeutics is developing the first of its kind plataform to produce any cell type in the body at industrial scale (>100L). By reimagining cell culture media from the ground up, we have developed negligible-cost media to cultivate and differentiate pluripotent stem cells for therapeutic applications. Currently, we are developing two cellulat therapies focused on two key areas, namely: cardiology and neurology.